Osteopontin is an oncogenic Vav1- but not wild-type Vav1-responsive gene: Implications for fibroblast transformation

Cancer Research

Volumn 66, Issue 12, 2006, Pages 6183-6191

  Schapira, Vered ^a   Lazer, Galit ^a   Katzav, Shulamit ^a  

^a HEBREW UNIVERSITY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR; GUANINE NUCLEOTIDE EXCHANGE FACTOR; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 9; OSTEOPONTIN; PROTEIN VAV1; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; VAV PROTEIN;

ANIMAL CELL; ARTICLE; CELL STRAIN 3T3; CELL TRANSFORMATION; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; FIBROBLAST; GENE CONTROL; GENE EXPRESSION; GENE REPRESSION; GENETIC ANALYSIS; GENETIC TRANSFECTION; GENETIC TRANSFORMATION; MOUSE; NONHUMAN; ONCOGENE; ONCOGENIC VAV1 GENE; PRIORITY JOURNAL; PROTEIN DEPLETION; SIGNAL TRANSDUCTION;

ANIMALS; CELL TRANSFORMATION, NEOPLASTIC; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FIBROBLASTS; GENE EXPRESSION; MICE; NIH 3T3 CELLS; OSTEOPONTIN; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-VAV; SIALOGLYCOPROTEINS; SIGNAL TRANSDUCTION; TRANSFECTION;

EID: 33745728149     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-05-3735     Document Type: Article

References (56)

1. Katzav S, Martin-Zanca D, Barbacid M. vav, a novel human oncogene derived from a locus ubiquitously expressed in hematopoietic cells. EMBO J 1989;8:2283-90.
2. Tybulewicz VL. Vav-family proteins in T-cell signaling. Curr Opin Immunol 2005;17:267-74.
3. Bustelo XR. Regulatory and signaling properties of the Vav family. Mol Cell Biol 2000;20:1461-77.
4. Hornstein I, Alcover A, Katzav S. Vav proteins, masters of the world of cytoskeleton organization. Cell Signal 2004;16:1-11.
5. Crespo P, Schuebel KE, Ostrom AA, et al. Phosphotyrosine-dependent activation of Rac-1 GDP/GTP exchange by the vav proto-oncogene product Nature 1997;385:169-72.
6. del Peso L, Hernandez-Alcoceba R, Embade N, et al. Rho proteins induce metastatic properties in vivo. Oncogene 1997;15:3047-57.
7. Katzav S, Cleveland JL, Heslop HE, et al. Loss of the amino-terminal helix-loop-helix domain of the vav proto-oncogene activates its transforming potential. Mol Cell Biol 1991;11:1912-20.
8. Coppola J, Bryant S, Koda T, et al. Mechanism of activation of the vav protooncogene. Cell Growth Differ 1991;2:95-105.
9. Abe K, Whitehead IP, O'Bryan JP, et al. Involvement of NH(2)-terminal sequences in the negative regulation of Vav signaling and transforming activity. J Biol Chem 1999;274:30410-8.
10. Khosravi-Far R, Chrzanowska-Wodnicka M, Solski PA, et al. Dbl and Vav mediate transformation via mitogen-activated protein kinase pathways that are distinct from those activated by oncogenic Ras. Mol Cell Biol 1994;14:6848-57.
11. Aghazadeh B, Lowry WE, Huang XY, et al. Structural basis for relief of autoinhibition of the Dbl homology domain of proto-oncogene Vav by tyrosine phosphorylation. Cell 2000;102:625-33.
12. Manetz TS, Gonzalez-Espinosa C, Arudchandran R, et al. Vav1 regulates phospholipase Cγ activation and calcium responses in mast cells. Mol Cell Biol 2001;21:3763-74.
13. Groysman M, Hornstein I, Alcover A, et al. Vav1 and Ly-GDI two regulators of Rho GTPases, function cooperatively as signal transducers in T cell antigen receptor-induced pathways. J Biol Chem 2002;277:50121-30.
14. Wu J, Katzav S, Weiss A. A functional T-cell receptor signaling pathway is required for p95vav activity. Mol Cell Biol 1995;15:4337-46.
15. Katzav S. Single point mutations in the SH2 domain impair the transforming potential of vav and fail to activate proto-vav. Oncogene 1993;8:1757-63.
16. Groysman M, Nagano M, Shaanan B, et al. Mutagenic analysis of Vav reveals that an intact SH3 domain is required for transformation. Oncogene 1998;17:1597-606.
17. Rittling SR, Chambers AF. Role of osteopontin in tumour progression. Br J Cancer 2004;90:1877-81.
18. Wai PY, Kuo PC. The role of osteopontin in tumor metastasis. J Surg Res 2004;121:228-41.
19. Teramoto H, Castellone MD, Malek RL, et al. Autocrine activation of an osteopontin-CD44-Rac pathway enhances invasion and transformation by H-RasV12. Oncogene 2005;24:489-501.
20. Hendrix MJ, Seftor EA, Seftor RE, et al. A simple quantitative assay for studying the invasive potential of high and low human metastatic variants. Cancer Lett 1987;38:137-47.
21. Medico E, Gentile A, Lo Celso C, et al. Osteopontin is an autocrine mediator of hepatocyte growth factor-induced invasive growth. Cancer Res 2001;61:5861-8.
22. Reynolds LF, de Bettignies C, Norton T, et al. Vav1 transduces T cell receptor signals to the activation of the Ras/ERK pathway via LAT, Sos, and RasGRP1. J Biol Chem 2004;279:18239-46.
23. Villalba M, Hernandez J, Deckert M, et al. Vav modulation of the Ras/MEK/ERK signaling pathway plays a role in NFAT activation and CD69 up-regulation. Eur J Immunol 2000;30:1587-96.
24. Costello PS, Walters AE, Mee PJ, et al. The Rho-family GTP exchange factor Vav is a critical transducer of T cell receptor signals to the calcium, ERK, and NF-κB pathways. Proc Natl Acad Sci U S A 1999;96:3035-40.
25. Cao Y, Janssen EM, Duncan AW, et al. Pleiotropic defects in TCR signaling in a Vav-1-null Jurkat T-cell line. EMBO J 2002;21:4809-19.
26. Crespo P, Bustelo XR, Aaronson DS, et al. Rac-1 dependent stimulation of the JNK/SAPK signaling pathway by Vav. Oncogene 1996;13:455-60.
27. Song JS, Haleem-Smith H, Arudchandran R, et al. Tyrosine phosphorylation of Vav stimulates IL-6 production in mast cells by a Rac/c-Jun N-terminal kinase-dependent pathway. J Immunol 1999;163:802-10.
28. Salojin KV, Zhang J, Delovitch TL. TCR and CD28 are coupled via ZAP-70 to the activation of the Vav/Rac-1-/PAK-1/p38 MAPK signaling pathway. J Immunol 1999;163:844-53.
29. Denhardt DT, Noda M. Osteopontin expression and function: role in bone remodeling. J Cell Biochem Suppl 1998;30-1:92-102.
30. Craig AM, Nemir M, Mukherjee BB, et al. Identification of the major phosphoprotein secreted by many rodent cell lines as 2ar/osteopontin: enhanced expression in H-ras-transformed 3T3 cells. Biochem Biophys Res Commun 1988;157:166-73.
31. Wu Y, Denhardt DT, Rittling SR. Osteopontin is required for full expression of the transformed phenotype by the ras oncogene. Br J Cancer 2000;83:156-63.
32. Tezuka K, Denhardt DT, Rodan GA, et al. Stimulation of mouse osteopontin promoter by v-Src is mediated by a CCAAT box-binding factor. J Biol Chem 1996;271:22713-7.
33. Chackalaparampil I, Peri A, Nemir M, et al. Cells in vivo and in vitro from osteopetrotic mice homozygous for c-src disruption show suppression of synthesis of osteopontin, a multifunctional extracellular matrix protein. Oncogene 1996;12:1457-67.
34. Hickey FB, England K, Cotter TG. Bcr-Abl regulates osteopontin transcription via Ras, PI-3K, aPKC, Raf-1, and MEK. J Leukoc Biol 2005;78:289-300.
35. Fernandez-Zapico ME, Gonzalez-Paz NC, Weiss E, et al. Ectopic expression of VAV1 reveals an unexpected role in pancreatic cancer tumorigenesis. Cancer Cell 2005;7:39-49.
36. Denhardt DT, Mistretta D, Chambers AF, et al. Transcriptional regulation of osteopontin and the metastatic phenotype: evidence for a Ras-activated enhancer in the human OPN promoter. Clin Exp Metastasis 2003;20:77-4.
37. Atkins KB, Simpson RU, Somerman MJ, et al. Stimulation of osteopontin mRNA expression in HL-60 cells is independent of differentiation. Arch Biochem Biophys 1997;343:157-63.
38. Chang PL, Tucker MA, Hicks PH, et al. Novel protein kinase C isoforms and mitogen-activated kinase kinase mediate phorbol ester-induced osteopontin expression. Int J Biochem Cell Biol 2002;34:1142-51.
39. Lai CF, Chaudhary L, Fausto A, et al. Erk is essential for growth, differentiation, integrin expression, and cell function in human osteoblastic cells. J Biol Chem 2001;276:14443-50.
40. Moses S, Franzen A, Lovdahl C, et al. Injury-induced osteopontin gene expression in rat arterial smooth muscle cells is dependent on mitogen-activated protein kinases ERK1/ERK2. Arch Biochem Biophys 2001;396:133-7.
41. Ye ZS, Baltimore D. Binding of Vav to Grb2 through dimerization of Src homology 3 domains. Proc Natl Acad Sci U S A 1994;91:12629-33.
42. Etienne-Manneville S, Hall A. Rho GTPases in cell biology. Nature 2002;420:629-35.
43. Van Aelst L, D'Souza-Schorey C. Rho GTPases and signaling networks. Genes Dev 1997;11:2295-322.
44. Olson MF, Pasteris NG, Gorski JL, et al. Faciogenital dysplasia protein (FGD1) and Vav, two related proteins required for normal embryonic development, are upstream regulators of Rho GTPases. Curr Biol 1996;6:1628-33.
45. Vicente-Manzanares M, Cruz-Adalia A, Martin-Cofreces NB, et al. Control of lymphocyte shape and the chemotactic response by the GTP exchange factor Vav. Blood 2005;105:3026-34.
46. Soga N, Connolly JO, Chellaiah M, et al. Rac regulates vascular endothelial growth factor stimulated motility. Cell Commun Adhes 2001;8:1-13.
47. 3-mediated adhesion are required for Vav1 association and Rho activation in leukocytes. J Biol Chem 2005;280:15422-9.
48. 2 integrin-dependent functions of neutrophils. J Cell Biol 2004;166:273-82.
49. 5. J Biol Chem 1995;270:2632-8.
50. 3 in smooth muscle migration to osteopontin in vitro. J Clin Invest 1995;95:713-24.
51. Katagiri Y, Murakami M, Mori K, et al. Non-RGD domains of osteopontin promote cell adhesion without involving v integrins. J Cell Biochem 1996;62:123-31.
52. Weber GF, Ashkar S, Glimcher MJ, et al. Receptor-ligand interaction between CD44 and osteopontin (Eta-1). Science 1996;271:509-12.
53. Herrlich P, Zoller M, Pals ST, et al. CD44 splice variants: metastasis meet lymphocytes. Immunol Today 1993;14:395-9.
54. Philip S, Bulbule A, Kundu GC. Osteopontin stimulates tumor growth and activation of promatrix metalloproteinase-2 through nuclear factor-κB- mediated induction of membrane type 1 matrix metalloproteinase in murine melanoma cells. J Biol Chem 2001;276:44926-35.
55. Tuck AB, Hota C, Chambers AF. Osteopontin (OPN)-induced increase in human mammary epithelial cell invasiveness is urokinase (uPA)-dependent. Breast Cancer Res Treat 2001;70:197-204.
56. Hornstein I, Pikarsky E, Groysman M, et al. The haematopoietic specific signal transducer Vav1 is expressed in a subset of human neuroblastomas. J Pathol 2003;199:526-33.